title: Blood pressure-independent ETA and AT1 receptor blocker effects on the coronaries of rats harboring human renin and angiotensinogen genes.
abstract: BACKGROUND
  Blood pressure-independent (BP) effects of angiotensin (Ang) II and endothelin (ET) on coronaries (remodeling) in high renin hypertension are incompletely understood.
  
  
  METHODS
  We studied the effects of subdepressor doses of Ang II receptor (AT1) blockade with losartan (10 mg/kg/day gavage) and endothelin A receptor (ETA) blockade with LU135252 (30 mg/kg/day) on the coronaries of rats harboring human renin and angiotensinogen genes (dTGR). Nontransgenic Sprague-Dawley rats were controls. The rats were treated between the ages of 6 and 10 weeks. Coronary cross-sectional area [CSA; 0.79 x (external diameter2 - internal diameter2)], cell proliferation, and infiltration of monocytes/macrophages were determined.
  
  
  RESULTS
  Monotherapy did not lower BP while combination treatment did (p < 0.05). All treatments reduced mortality (p < 0.01). CSA was decreased by all treatments compared to vehicle, independent of blood pressure (p < 0.05). Extensive proliferation by PCNA staining and infiltration of ED-1-positive cells was diminished by both treatment and the combination.
  
  
  CONCLUSIONS
  The data show that Ang II promotes coronary inflammation and remodeling, in part independent of blood pressure but dependent upon ET signaling. Combination treatment directed at both pathways may improve outcome, independent of blood pressure reduction.
authors.affiliation: Franz Volhard Clinic, HELIOS Klinikum-Berlin and Max Delbrück Center, Medical Faculty of the Charité, Humboldt University of Berlin, Germany. s.gerbaulet@martinus-duesseldorf.de
authors.forename: Stephan P
authors.initials: SP
authors.lastname: Gerbaulet
authors.forename: Jochen
authors.initials: J
authors.lastname: Krämer
authors.forename: Jürgen
authors.initials: J
authors.lastname: Bohlender
authors.forename: Rainer
authors.initials: R
authors.lastname: Dietz
authors.forename: C Michael
authors.initials: CM
authors.lastname: Gross
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D000808:Angiotensinogen / Q000235:genetics*; D000818:Animals; D030801:Animals, Genetically Modified; D001011:Aorta / Q000473:pathology; D001794:Blood Pressure / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D003331:Coronary Vessels / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D004195:Disease Models, Animal; D065130:Endothelin A Receptor Antagonists; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000473:pathology*; D008264:Macrophages / Q000187:drug effects; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D012083:Renin / Q000235:genetics*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D065130:Endothelin A Receptor Antagonists; D000808:Angiotensinogen; D012083:Renin